Lymph Node Status in Breast Cancer Does Not Predict Tumor Biology.

CONCLUSIONS: RS distribution among N0, N1mi, and N+ patients is similar, suggesting a spectrum of biology and potential chemotherapy benefit exists among node-negative and node-positive ER+/HER2- breast cancer patients. If RxPONDER does not show a chemotherapy benefit in N+ patients with a low RS result, our findings indicate that substantial numbers of patients could be spared the burden of chemotherapy.
PMID: 29968028 [PubMed - as supplied by publisher]

Source: Ann Oncol - July 2, 2018 Category: Cancer & Oncology Authors: Bello DM, Russell C, McCullough D, Tierno M, Morrow M Tags: Ann Surg Oncol Source Type: research